Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Europe waits

3Q Financial Market Preview

Europe waits

The markets are up in Europe and share volumes have increased, indicating a strengthening in investor enthusiasm, but no public companies have yet dared to seek financing rounds. The dilemma for European companies is judging when the markets will open and if they can be ready in time. Unlike in the U.S., European companies cannot so easily raise money through convertible debt, PIPEs and IPOs, making timing an offerings window more crucial.

Besides this, institutional European investors are concentrating on opportunities in the U.S. According to most bankers, about 80% of dedicated EU biotech cash is invested in U.S. companies. The reason is clear. "Money is being directed towards product companies, and quite simply there are more product companies in the U.S.," said Greg Parekh, head of European healthcare

Read the full 1325 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE